Back to Search
Start Over
Corrigendum: A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer.
- Source :
- Frontiers in Oncology; 11/16/2021, Vol. 11, p1-2, 2p
- Publication Year :
- 2021
-
Abstract
- B The survival numbers were incorrect. b A correction has been made to B I Results, Survival: i b B "PFS at 12, 18, and 24 months was 83.5% (95%CI: 77.6-89.7), 65.5 (95%CI: 57.6-74.4), and 53.1% (95%CI: 43.8-64.3), respectively. Keywords: chemoradiotherapy; immunotherapy; stage III; unresectable; NSCLC EN chemoradiotherapy immunotherapy stage III unresectable NSCLC 1 2 2 11/19/21 20211116 NES 211116 In the original article there was an error. Chemoradiotherapy, immunotherapy, unresectable, stage III, NSCLC. [Extracted from the article]
- Subjects :
- NON-small-cell lung carcinoma
CHEMORADIOTHERAPY
SCIENTIFIC observation
Subjects
Details
- Language :
- English
- ISSN :
- 2234943X
- Volume :
- 11
- Database :
- Complementary Index
- Journal :
- Frontiers in Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 153624775
- Full Text :
- https://doi.org/10.3389/fonc.2021.802949